Lymphoma

P=N/A, N=5, Terminated, University of Colorado, Denver | Trial primary completion date: Nov 2024 --> Jul 2025

P1, N=46, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Jun 2027 --> Feb 2030 | Trial primary completion date: Jun 2027 --> Feb 2030

P1, N=39, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting

The therapeutic use of isotonic bicarbonate solution is limited owing to paradoxical intracellular acidosis. Tris-hydroxymethyl aminomethane rapidly corrects intracellular acidosis, restoring hepatic lactate clearance through the Cori cycle.

This analysis identified an ER-resident protein called STEEP1, previously implicated in support of trafficking of the DNA sensor STING, as a key LMP1 partner.We found that STEEP1 associates with LMP1 and supports LMP1 trafficking out of the endoplasmic reticulum to cellular signaling sites. As STEEP1 knockout impaired LMP1 function and LCL survival, our study identifies the STEEP1/LMP1 complex as a therapeutic target.

Myeloid cells exhibited expression of immunomodulatory genes (RUNX3, DDIT4, IL4I1), and malignant T-cells expressed exhaustion-associated markers (CXCL13, SOCS3, F2R, ETV1), as opposed to AD and healthy control samples. Thus, our results provide a novel insight into the immune-stroma crosstalk in the tissue microenvironment of early-stage MF vs. AD skin lesions.

Both current classifications recognize some categories of BCL2-R negative FL including the "predominantly diffuse FL" (WHO-HAEM5) (overlapping with the "BCL2-R negative/CD23 positive follicle center lymphoma" according to the ICC) often presenting in the inguinal region with an indolent course; the paediatric-type FL and the testicular FL affecting children or young adults. The recently described "follicle center lymphoma of the lower female genital tract" shows some similarities with primary cutaneous follicle center lymphoma.

High plasma cell-like phenotype signatures were linked to poorer progression-free survival (PFS) but greater benefit from R-CHOP plus bortezomib, while low-signature patients achieved better PFS with R-CHOP alone. These findings characterize the transcriptomic features of distinct plasma cell-like phenotypes in DLBCL, providing new insights into its prognostic relevance and potential for individualized treatment strategies.

Overall, duvelisib plus venetoclax was active in high-risk R/R CLL/SLL and RT, though serious adverse events occurred, including immune-mediated toxicities. NCT03534323.

sgp130Fc confers renoprotective effects in a murine model of sepsis by selectively targeting the IL-6 trans-signaling pathway and modulating STAT3/NF-κB signaling to inhibit inflammation and apoptosis. These findings highlight the therapeutic potential of sgp130Fc in SAKI and support further clinical investigation.

Hence, by splicing factors interactions, ALT interferes with host gene expression. Our results uncover a novel mechanism that shifts gene expression from the host to the virus late during the viral replication cycle to efficiently produce progeny virus and potentially antagonize host immune defenses.